鎶楄叓鐦ゆ姉鐢熺礌鏄敱寰敓鐗╃敘(ch菐n)鐢熺殑鍏锋湁鎶楄叓鐦ゆ椿鎬х殑鍖栧(xu茅)鐗╄唱(zh矛)銆傞�欑ó寰敓鐗╃敘(ch菐n)鐢熺殑鎶楃敓绱犲叿鏈�鐛�(d煤)鐗圭殑鍒嗗瓙绲�(ji茅)妲�(g貌u)銆佹柊绌庣殑浣滅敤姗�(j墨)鍒�鍜岄珮鏁堢殑鐢熺墿娲绘��[1]銆傜洰鍓�锛屾姉鑵槫鎶楃敓绱犵殑鐮旂┒宸插彇寰楀鏂归潰閫�(j矛n)灞�锛屽苟涓斿绋姉鑵槫鎶楃敓绱犳噳(y墨ng)鐢ㄤ簬鑷ㄥ簥锛屽潎鏀跺埌浜嗚壇濂界殑鐧傛晥銆傚鏀剧窔鑿岀礌銆�楣介吀闃块湁绱犮��琛ㄦ煍姣旀槦鍜屽崥渚嗛湁绱犵瓑[2][3]銆傜櫨闈堝▉浣滅偤灏堟キ(y猫)瑭﹀姂渚涙噳(y墨ng)鍟�锛屼緵鎳�(y墨ng)鎶楄叓鐦ゆ姉鐢熺礌銆佹姉鑵槫鍖栧悎鐗╃瓑澶氱ó鐢�(ch菐n)鍝�銆�
鈻� 鐢�(ch菐n)鍝佸垪琛�
| 鐢�(ch菐n)鍝佺法铏�(h脿o) |
鑻辨枃鍚嶇ū |
涓枃鍚嶇ū |
CAS |
浣滅敤闈堕粸(di菐n) |
| 338112 |
Actinomycin D, 98% |
鏀剧窔鑿岀礌 D, 98% |
50-76-0 |
N/A |
| 113424 |
Doxorubicin hydrochloride, 98% |
楣介吀闃块湁绱�, 98% |
25316-40-9 |
DNA topoisomerase II鎶戝埗鍔� |
| 194237 |
Epirubicin hydrochloride, 98% |
琛ㄦ煍姣旀槦楣介吀楣�, 98% |
56390-09-1 |
DNA topoisomerase II鎶戝埗鍔� |
| 573584 |
Geldanamycin, 99% |
鏍肩埦寰烽湁绱�, 99% |
30562-34-6 |
HSP90鎶戝埗鍔� |
| 135072 |
Mithramycin A |
鍏夎紳闇夌礌A |
18378-89-7 |
Polymerase鎶戝埗鍔� |
| 948477 |
Rapamycin, 98% |
闆峰笗闇夌礌, 98% |
53123-88-9 |
mTOR鎶戝埗鍔� |
| 282611 |
Wortmannin, 98% |
娓ユ浖闈掗湁绱�, 98% |
19545-26-7 |
PI3K鎶戝埗鍔� |
| BIZ0413 |
Zeocin |
鍗氫締闇夌礌 |
11031-11-1 |
DNA Synthesis鎶戝埗鍔� |
鏇村鐢�(ch菐n)鍝�
References
[1] Wang L, Cheng X, Huang C, et al. Rapamycin protects cardiomyocytes against anoxia/reoxygenation injury by inducing autophagy through the PI3k/Akt pathway[J]. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35(1): 10-15.
[2] Baluk P, Yao L C, Flores J, et al. Rapamycin Reverses Lymphatic Abnormalities In A Transgenic Mouse Model Of Pulmonary Lymphangiectasia[M]//B52. NEONATAL LUNG DISEASE: FROM BENCH TO BABIES. American Thoracic Society, 2016: A3866-A3866.
[3] Das D, Rameshbabu A P, Ghosh P, et al. Biocompatible nanogel derived from functionalized dextrin for targeted delivery of doxorubicin hydrochloride to MG 63 cancer cells[J]. Carbohydrate Polymers, 2017, 171: 27-38.
鈻� 鐢�(ch菐n)鍝佸垪琛�
| 鐢�(ch菐n)鍝佺法铏�(h脿o) |
鑻辨枃鍚嶇ū |
涓枃鍚嶇ū |
CAS |
浣滅敤闈堕粸(di菐n) |
| 381488 |
Ara-G hydrate, 98% |
闃跨硸槌ヨ嫹, 98% |
38819-10-2 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 274584 |
Carboplatin, 98% |
纰抽墤, 98% |
41575-94-4 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 258050 |
2-Chloro-2'-deoxyadenosine, 99% |
2-姘�-2'-鑴哀鑵鸿嫹, 99% |
4291-63-8 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 275688 |
cis-Diamineplatinum(II) dichloride, 99% |
闋嗗紡-浜屾皑浜屾隘鍖栭墤, 99% |
15663-27-1 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 180939 |
5-Fluorouracil, 99% |
5-姘熷翱鍢у暥, 99% |
51-21-8 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 271269 |
Gemcitabine hydrochloride, 99% |
楣介吀鍚夎タ浠栨勘, 99% |
122111-03-9 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 251696 |
Oxaliplatin, 95% |
濂ф矙鍒╅墤, 95% |
61825-94-3 |
DNA/RNA Synthesis鎶戝埗鍔� |
| 996037 |
Afatinib, 98% |
闃挎硶鏇垮凹, 98% |
850140-72-6 |
EGFR鎶戝埗鍔� |
| 341249 |
Erlotinib, 98% |
鍩冪緟鏇垮凹, 98% |
183321-74-6 |
EGFR鎶戝埗鍔� |
| 831262 |
Lapatinib, 98% |
鎷夊笗鏇垮凹, 98% |
231277-92-2 |
EGFR鎶戝埗鍔� |
| 795123 |
Lapatinib ditosylate, 98% |
浜岀敳鑻：閰告媺甯曟浛灏�, 98% |
388082-77-7 |
EGFR鎶戝埗鍔� |
| 625238 |
Entinostat, 99% |
鎭╂浛璜剧壒, 99% |
209783-80-2 |
HDAC鎶戝埗鍔� |
| 837002 |
Panobinostat, 98% |
甯曟瘮鍙镐粬, 98% |
404950-80-7 |
HDAC鎶戝埗鍔� |
| 303595 |
Trichostatin A, 98% |
鏇插彜鏌宠弻绱燗, 98% |
58880-19-6 |
HDAC鎶戝埗鍔� |
| 1349106 |
Ruxolitinib phosphate salt, 99% |
榄储鍒╂浛灏肩７閰搁菇, 99% |
1092939-17-7 |
JAK鎶戝埗鍔� |
| 1430418 |
Tofacitinib citrate, 99% |
妾告閰告墭娉曟浛灏�, 99% |
540737-29-9 |
JAK鎶戝埗鍔� |
| 912849 |
Tofacitinib, 99% |
鎵樻硶鏇垮凹, 99% |
477600-75-2 |
JAK鎶戝埗鍔� |
| 951485 |
Ruxolitinib, 99% |
榄储鏇垮凹, 99% |
941678-49-5 |
JAK鎶戝埗鍔� |
| 369172 |
6-Amino-3-methylpurine, 90% |
6-姘ㄥ熀-3-鐢插熀鍢屽懁, 90% |
5142-23-4 |
PI3K鎶戝埗鍔� |
| 268623 |
Quercetin, 98% |
妲茬毊绱�, 98% |
117-39-5 |
PI3K鎶戝埗鍔� |
| 812864 |
Axitinib, 98% |
闃胯タ鏇垮凹, 98% |
319460-85-0 |
VEGFR2鎶戝埗鍔� |
| 1239124 |
Ponatinib, 99% |
甯曠磵鏇垮凹, 99% |
943319-70-8 |
VEGFR2鎶戝埗鍔� |
| 814262 |
Vandetanib, 99% |
鍑″痉浠栧凹, 99% |
443913-73-3 |
VEGFR2鎶戝埗鍔� |
| 1109982 |
Vatalanib dihydrochloride, 99% |
鐡︿粬鎷夊凹鍫夸簩楣介吀楣�, 99% |
212141-51-0 |
VEGFR2鎶戝埗鍔� |
鏇村鐢�(ch菐n)鍝�
鈻�鐩搁棞(gu膩n)鐢�(ch菐n)鍝�